Furthermore, the immunohistochemical analysis of xenograft tumors also demonstrated impaired FOXM1 expression in Cr-Y575F cell line-derived tumors, as well as in wild-type cell-derived tumors subjected to nilotinib administration (Fig. 7D), indicating a strong correlation between ABL1-regulated FOXM1 expression and tumor development. Here, FOXM1 is linked to neoplasm.